Stock listing

KRX:298380 ABL Bio, Inc. (에이비엘바이오) 주가

Follow ABL Bio, Inc. into a list and get an email when it puts out news.

Share price · KRX:298380

₩35,250 KRW -750 (-2.1%)

Close on Nov 20, 2026

Past year -80.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
₩34,900 – ₩37,200 KRWNov 20, 2026
Volume
263,294 sharesNov 20, 2026
Market cap
₩1.97T KRWAt the close on Nov 20, 2026 · price × 55.99M shares outstanding
52-week range
₩33,900 – ₩257,500 KRWLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
₩16.73B KRWMedian day 278,773 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
ABL Bio, Inc. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:298380 · KRW, adjusted for splits

DayCloseChange%OpenHighLowVolume
₩35,250-750-2.1%₩36,500₩37,200₩34,900263,294
₩36,000-1,850-4.9%₩38,050₩38,750₩35,750353,782
₩37,850-550-1.4%₩37,600₩39,850₩37,300257,135
₩38,400-2,250-5.5%₩41,300₩42,100₩37,950295,559
₩40,65000.0%₩41,100₩44,500₩40,300278,951
₩40,650-1,850-4.4%₩41,900₩43,650₩39,900440,663
₩42,500+5,050+13.5%₩37,200₩42,850₩37,200702,129
₩37,450+1,850+5.2%₩36,750₩38,100₩36,050196,067
₩35,600-450-1.2%₩35,900₩37,400₩33,900278,595
₩36,050-3,450-8.7%₩35,700₩37,500₩35,000470,710
₩39,500+1,050+2.7%₩39,750₩43,950₩38,850591,496
₩38,450+150+0.4%₩38,350₩38,500₩35,650376,273
₩38,300-1,450-3.6%₩39,000₩39,550₩38,000202,887
₩39,750+550+1.4%₩38,900₩40,350₩38,600211,198
₩39,200-1,800-4.4%₩40,300₩40,800₩38,250265,908
₩41,000-800-1.9%₩42,050₩42,450₩40,250251,109
₩41,800+950+2.3%₩40,900₩42,800₩40,900292,476
₩40,850+50+0.1%₩41,000₩42,600₩40,450234,136
₩40,800-3,450-7.8%₩42,800₩43,500₩40,750206,594
₩44,250-250-0.6%₩44,050₩44,600₩42,750196,579
₩44,500-2,250-4.8%₩46,500₩46,750₩44,200193,055
₩46,750+2,050+4.6%₩45,700₩47,400₩45,250219,041
₩44,700-1,950-4.2%₩45,650₩46,400₩43,700198,179
₩46,650+3,300+7.6%₩42,950₩47,600₩42,300496,603
₩43,350+2,800+6.9%₩40,950₩44,800₩40,950386,501
₩40,550-2,550-5.9%₩41,200₩41,850₩39,700419,454
₩43,100-400-0.9%₩43,100₩44,400₩42,450244,758
₩43,500-2,100-4.6%₩43,900₩44,000₩41,700405,165
₩45,600-2,400-5.0%₩47,700₩48,450₩45,350302,528
₩48,000-3,100-6.1%₩50,100₩50,300₩47,650407,458
₩51,100-1,400-2.7%₩53,700₩54,200₩51,100285,829
₩52,500+1,100+2.1%₩51,900₩54,100₩51,100310,705
₩51,400-2,200-4.1%₩53,600₩54,700₩50,000266,151
₩53,600+5,100+10.5%₩48,300₩53,700₩47,350551,114
₩48,500-800-1.6%₩49,050₩50,200₩48,250270,560
₩49,300-900-1.8%₩49,400₩49,450₩48,050380,995
₩50,200-600-1.2%₩51,900₩52,100₩49,750353,309
₩50,800-300-0.6%₩49,700₩51,700₩49,350482,461
₩51,100-2,800-5.2%₩53,300₩53,400₩50,800457,081
₩53,900-2,100-3.8%₩55,300₩55,600₩53,300560,567
₩56,000-2,100-3.6%₩57,700₩57,900₩55,600429,127
₩58,100+200+0.3%₩57,900₩59,200₩57,300241,907
₩57,900-1,400-2.4%₩56,600₩58,300₩54,100829,910
₩59,300-5,600-8.6%₩65,000₩67,300₩57,750944,589
₩64,900-1,200-1.8%₩65,300₩66,300₩62,700152,510
₩66,100-1,700-2.5%₩65,500₩66,800₩65,400118,159
₩67,800-1,200-1.7%₩67,600₩68,600₩65,500296,833
₩69,000+800+1.2%₩67,700₩69,500₩67,700168,369
₩68,200-2,900-4.1%₩70,900₩71,400₩68,100192,626
₩71,100-300-0.4%₩71,500₩72,100₩70,500147,749
₩71,400+3,800+5.6%₩68,500₩71,900₩68,400169,255
₩67,600-1,700-2.5%₩70,300₩71,400₩66,900244,594
₩69,300-1,700-2.4%₩69,000₩72,200₩67,600258,963
₩71,000-1,700-2.3%₩72,100₩72,900₩70,500173,680
₩72,700-4,200-5.5%₩74,200₩74,300₩70,200328,730
₩76,900+900+1.2%₩78,100₩81,300₩75,600367,300
₩76,000+1,400+1.9%₩73,500₩77,200₩73,500241,871
₩74,60000.0%₩75,400₩76,700₩74,000152,704
₩74,600-1,200-1.6%₩74,100₩74,800₩70,500318,732
₩75,800+600+0.8%₩75,200₩77,500₩74,200202,899
₩75,200-7,300-8.8%₩79,800₩80,000₩74,600286,381
₩82,500+2,800+3.5%₩83,900₩85,000₩79,300272,917
Ticker
KRX:298380
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
KRX
Currency
KRW

What changed lately

Latest news

All ABL Bio, Inc. news

ABL Bio, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
1 in the last 12 months · 1 in all · newest Mar 30, 2026 · oldest 2026

Valuation

EV/sales 52.7× against a median of 14.5×: 6th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
₩1.81T KRW
P/E
Loss
EV/sales
52.7×
EV/EBITDA
Negative EBITDA
Price/book
11.5×
Gross margin
100.0%
Operating margin
−250.9%
Net margin
−229.4%
Debt to equity
0.0×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
ABL Bio, Inc. · KRX:298380US$1.48BUS$1.35Bn/a52.7×n/a11.5×−229.4%0.0×n/a
Recursion Pharmaceuticals, Inc. · NASDAQ:RXRXUS$1.53BUS$987.7Mn/a14.5×n/a1.7×−697.1%0.0×2.83
Alvotech · NASDAQ:ALVOUS$1.47BUS$2.78Bn/a5.7×31.4×n/a−36.5%n/a0.90
PELL Bio-Med Technology Co Ltd · TWSE:6949US$1.46BUS$1.40Bn/a1,591×n/a18.7×n/a0.1×n/a
Mesoblast Limited · ASX:MSBUS$1.46BUS$1.42Bn/a82.4×n/a2.4×−593.9%0.2×n/a
Voronoi, Inc. · KRX:310210US$1.44BUS$1.40Bn/an/an/a27.9×n/a0.5×n/a
Damora Therapeutics, Inc. · NASDAQ:DMRAUS$1.44BUS$910.0Mn/an/an/a2.9×n/a0.0×0.88
Vir Biotechnology, Inc. · NASDAQ:VIRUS$1.44BUS$1.07Bn/a3.5×n/a1.6×−61.0%0.1×1.82
LigaChem Biosciences Inc. · KRX:141080US$1.43BUS$1.15Bn/a15.5×n/a4.8×−180.9%0.0×n/a
Kailera Therapeutics, Inc. · NASDAQ:KLRAUS$1.43BUS$539.5Mn/an/an/a1.4×n/a0.0×1.28
Sarepta Therapeutics, Inc. · NASDAQ:SRPTUS$1.43BUS$1.41Bn/a0.7×n/a0.9×−5.9%0.6×1.70
Median of the othersUS$1.44BUS$1.27B14.5×31.4×2.4×−121.0%0.1×1.49

Forecasts

Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.

Price target
270000.00 KRW · Analysts' mean
EPS, year to Dec 2026
-59.00 · 2 analysts
Revenue, year to Dec 2026
89B · 1 analyst

Team and board

OfficerRole
Sang Hoon LeePresident (CEO)
Jaecheon Jerry LeeChief Financial Officer
Hakju KwonSenior Vice President, Head of Neuroscience & NCD
Eunkyung KimChief Medical & Clinical Development Officer
Jaeho JungChief of Discovery
Jungdae KimChief Operations Officer
Sung-Ju MoonChief Technology Officer
Weon Kyoo YouChief Scientific Officer

Events

QuarterResultsShare move
Q1 2026May 11, 2026 · Before open−1.8%
Q3 2025Nov 10, 2025 · Before open−0.8%
Q2 2025Aug 11, 2025 · Before open+4.0%
Q1 2025May 13, 2025 · Before open+3.4%
Q4 2024Feb 13, 2025 · Before open−4.9%
Q3 2024Nov 8, 2024 · After close+7.8%
Q2 2024Aug 9, 2024 · After close+3.9%
Q1 2024May 14, 2024 · After close+2.3%
Q4 2023Mar 29, 2024 · Before open+8.2%
Q3 2023Nov 10, 2023 · After close−2.4%
All 20 quarters
QuarterResultsShare move
Q2 2023Aug 11, 2023 · After close−3.1%
Q1 2023May 15, 2023 · After close−1.3%
Q4 2022Feb 10, 2023 · After close+0.2%
Q3 2022Nov 14, 2022 · After close+9.6%
Q2 2022Aug 12, 2022 · Before open−3.7%
Q1 2022May 16, 2022 · Before open+1.4%
Q4 2021Feb 11, 2022 · Before open−8.1%
Q3 2021Nov 12, 2021+3.0%
Quarter to Jun 30, 2021Aug 12, 2021−5.8%
Quarter to Mar 31, 2021May 14, 2021+4.1%

Open Events

Financials

Annual, in KRW

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue79.3B33.4B65.5B67.3B5.33B8.10B3.99B1.26B71.4M0
Cost of revenue105.2M67.3M
Gross profit79.3B33.4B65.5B67.3B5.33B8.10B3.96B1.15B4.11M
Research and development93.0B74.1B52.0B48.4B41.0B52.8B39.6B18.1B6.67B
Selling, general and administrative14.5B13.7B10.9B8.85B12.8B11.3B10.1B5.98B2.34B1.09B
Operating income-40.3B-59.4B-2.62B906.5M-52.3B-59.6B-40.4B-24.0B-9.65B-3.52B
Depreciation and amortization3.45B2.23B2.59B2.32B2.16B2.06B1.65B621.0M403.5M154.5M
EBITDA-36.8B-57.1B-27.3M3.23B-50.1B-57.6B-38.8B-23.4B-9.25B-3.36B
Interest expense993.0M36.0M2.15B1.33B42.0M72.8M95.9M000
Income before tax-37.9B-55.5B-2.65B3.21B-43.6B-55.6B-37.0B-117.2B-74.7B-13.7B
Net income-37.8B-55.5B-2.65B3.21B-43.6B-55.6B-37.0B-117.2B-74.7B-13.7B
Earnings per share, basic-685.83-1,150.11-55.2667.33-924.34-1,202.39-816.82-2,629.33-3,874.39-709.45

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents112.0B56.3B28.1B25.1B21.6B40.7B91.1B122.0B2.00B5.34B
Short-term investments2.96B84.4B43.1B53.2B22.1B29.7B42.1B17.9B7.17B
Receivables59.1B616.7M50.9M451.8M83.9M1.19B442.2M5.70B
Current assets176.1B144.2B75.5B80.5B45.5B71.9B134.7B161.1B9.44B5.69B
Property, plant and equipment85.4B76.0B6.71B3.30B4.07B5.04B2.70B1.92B1.48B
Total assets280.9B232.0B160.1B185.2B65.5B99.9B142.9B168.9B20.4B7.53B
Current liabilities123.5B63.4B41.8B72.2B8.75B7.97B9.33B11.6B1.34B303.0M
Long-term debt043.0B40.0B07.63B2.33B
Total debt555.3M1.08B7.63B2.33B
Total liabilities124.2B64.7B86.1B115.7B9.50B9.23B10.9B11.9B106.3B19.6B
Shareholders' equity154.7B167.3B74.1B69.5B56.0B90.7B132.0B157.0B-86.0B-12.1B
Shares outstanding55.1M48.3M47.9M47.7M47.1M46.2M45.3M44.6M19.3M19.3M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-41.3B-69.4B-28.4B72.1B-40.6B-47.3B-23.9B-12.7B-7.14B-3.12B
Capital spending-20.7B-9.06B-5.84B-2.06B-1.24B-434.7M-1.59B-1.15B-802.5M-2.13B
Free cash flow-61.9B-78.5B-34.2B68.5B-41.9B-47.9B-25.4B-13.8B-7.95B-5.24B
Cash from investing-47.2B29.9B-71.2B20.2B-3.63B-8.26B-22.8B-16.2B-2.13B
Cash from financing144.6B1.44B4.65B284.1M598.3M-47.5M155.6B20.0B10.6B
Share buybacks145.9B1.72B5.75B1.26B1.50B651.9M160.0B4.01B3.56B
Change in cash55.7B28.2B2.93B3.55B-19.1B-50.5B-30.9B120.0B-3.34B5.34B

Open Financials

Cap table

Built by 6ix from ABL Bio, Inc.’s releases

Common shares
55,987,463
Fully diluted
55,987,463

Fully diluted

LineShares
Common shares55,987,463

Share count over time

CountShares
Nov 22, 202655,987,463

Open Cap table

Shareholders

Funds

HolderSharesValueAs of
Vanguard Total International Stock Index Fund620KUS$28.7MJul 31, 2026
iShares Core MSCI Emerging Markets ETF432KUS$32.1MMay 31, 2026
Vanguard Developed Markets Index Fund414KUS$26.7MJun 30, 2026
Vanguard Ftse All-World Ex-Us Index Fund99,733US$4.62MJul 31, 2026
Schwab International Equity ETF88,955US$6.61MMay 31, 2026
iShares Core MSCI Total International Stock ETF56,753US$2.63MJul 31, 2026
Vanguard Pacific Stock Index Fund45,262US$2.1MJul 31, 2026
Vanguard Total World Stock Index Fund35,982US$1.67MJul 31, 2026
Franklin FTSE South Korea ETF32,136US$2.06MJun 30, 2026
State Street(R) SPDR(R) Portfolio Developed World ex-US ETF31,695US$2.04MJun 30, 2026
All 33 holders
HolderSharesValueAs of
College Retirement Equities Fund - Total Global Stock Account27,052US$1.75MJun 30, 2026
Avantis Emerging Markets Equity ETF23,584US$1.75MMay 31, 2026
Fidelity Total International Index Fund22,553US$1.03MJul 31, 2026
State Street Global All Cap Equity ex-U.S. Index Portfolio12,226US$785KJun 30, 2026
Fidelity ZERO International Index Fund12,041US$551KJul 31, 2026
Columbia EM Core ex-China ETF9,757US$627KJun 30, 2026
iShares MSCI Emerging Markets Small-Cap ETF8,619US$639KMay 31, 2026
WisdomTree Emerging Markets ex-State-Owned Enterprises Fund8,229US$528KJun 30, 2026
Vanguard ESG International Stock ETF7,943US$589KMay 31, 2026
The Emerging Markets Series5,576US$258KJul 31, 2026
Dimensional Emerging Core Equity Market ETF4,898US$229KJul 31, 2026
Fidelity Flex International Index Fund4,313US$198KJul 31, 2026
Parametric Tax-Managed Emerging Markets Fund3,650US$236KJun 30, 2026
VIP International Index Portfolio1,439US$93,041Jun 30, 2026
Parametric Emerging Markets Fund800US$37,083Jul 31, 2026
Destinations International Equity Fund667US$49,436May 31, 2026
Hartford Multifactor Emerging Markets ETF556US$26,051Jul 31, 2026
FlexShares Morningstar Emerging Markets Factor Tilt Index Fund460US$21,553Jul 31, 2026
Goldman Sachs MarketBeta Emerging Markets Equity ETF374US$27,771May 31, 2026
BNY Mellon Emerging Markets Equity ETF280US$13,119Jul 31, 2026
Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF242US$17,969May 29, 2026
Avantis Emerging Markets ex-China Equity ETF212US$15,729May 31, 2026
Franklin FTSE Asia ex Japan ETF189US$12,138Jun 30, 2026

Big stakes

StakeFiling
LeesanghoonLarge holding report (5%)

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Eunkyung KimChief Medical & Clinical Development Officer · Since at least Nov 5, 2026
Hakju KwonSenior Vice President, Head of Neuroscience & NCD · Since at least Nov 5, 2026
Jaecheon Jerry LeeChief Financial Officer · Since at least Nov 5, 2026
Jaeho JungChief of Discovery · Since at least Nov 5, 2026
Jungdae KimChief Operations Officer · Since at least Nov 5, 2026
Sang Hoon LeePresident (CEO) · Since at least Nov 5, 2026
Sung-Ju MoonChief Technology Officer · Since at least Nov 5, 2026
Weon Kyoo YouChief Scientific Officer · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about ABL Bio, Inc.